HOWLNasdaqPharmaceutical PreparationsFiscal year ends December 31

Werewolf Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$1.04+0.06 (+6.12%)

Close on Oct 19, 2026

Market cap: $50.54M
P/E (TTM): –
Dividend yield: –

Werewolf Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Research & Development	6.16	8.18	6.93	12	13	13	16	13	15	13	9.65	11	9.58	12	16	13	14	11	13	9.79	7.27	4.82	5.29	4.81	3.78	2.76
General & Administrative	7.68	5.09	2.49	4.09	4.40	4.87	4.62	4.60	4.83	5.00	4.81	4.31	4.57	4.98	4.60	4.44	5.23	4.42	4.48	4.01	3.69	2.64	2.11	1.24	1.29	1.13
Operating Expenses	14	13	9.42	16	18	18	20	17	20	18	14	15	14	17	20	18	19	15	18	14	11	7.45	7.39	6.05	5.07	3.89
Operating Income	7.16	-13	-9.42	-16	-18	-18	-20	-17	-19	-17	-13	-9.25	-6.07	-12	-13	-13	-15	-15	-18	-14	-11	-7.45	-7.39	-6.05	-5.07	-3.89
Interest Expense	0.48	1.37	1.37	1.34	1.30	1.26	1.27	1.24	1.14	1.00	1.01	1.00	0.96	0.17	–	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	0.28	0.43	0.56	0.70	0.85	1.00	1.31	1.60	1.79	1.97	1.98	1.97	1.95	1.52	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-3.49	-0.26	1.04	-0.64	-0.44	-0.10	-0.05	0.45	1.71	0.97	0.96	0.97	0.97	0.24	1.25	0.60	0.38	0.02	0.02	0.04	0.04	0.02	-0.01	-0.02	7.32	0.07
Merger & Restructuring Charges	1.38	4.31	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	3.67	-14	-8.38	-16	-18	-18	-20	-17	-17	-16	-12	-8.29	-5.10	-12	-12	-12	-15	-15	-18	-14	-11	-7.44	-7.40	-6.07	2.26	-3.83
Net Income to Common	–	-14	-8.38	-16	-18	-18	-20	-17	-17	–	-12	-8.29	-5.10	–	-12	-12	-15	-15	-18	-14	-68	-102	-21	-6.07	2.23	-3.83
EPS (Basic)(per share)	0.08	-0.28	-0.17	-0.36	-0.40	-0.40	-0.46	-0.38	-0.40	-0.39	-0.33	-0.23	-0.14	-0.34	-0.39	-0.40	-0.53	-0.56	–	-0.51	-3.82	-83.36	-17.79	-6.61	2.35	-4.58
EPS (Diluted)(per share)	0.08	-0.28	-0.16	-0.36	-0.40	-0.40	-0.45	-0.38	-0.43	-0.39	-0.33	-0.23	-0.14	-0.34	-0.39	-0.40	-0.53	-0.56	–	-0.51	-3.82	-83.36	-17.79	-6.61	0.22	-4.58
Shares Outstanding (Basic, Weighted)(shares)	49	49	48	46	45	45	44	44	44	42	37	36	36	35	31	30	28	27	27	27	18	1.23	1.16	0.92	0.95	0.84
Shares Outstanding (Diluted, Weighted)(shares)	49	49	52	46	45	45	45	44	44	42	37	36	36	35	31	30	28	27	27	27	18	1.23	1.16	0.92	10	0.84

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -123.9%

Financial strength

Current ratio: 2.91
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 279.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.10
Dividend yield: –